ShanghaiTech University Announces Research Collaboration and License Agreement with Jing Medicine Technology (Shanghai) Ltd. for the Discovery and Development of Protein Degradation Drug Candidates

ShanghaiTech University and Jing Medicine Technology (Shanghai) Ltd. announced an over $100 million USD strategic collaboration to discover and develop novel small molecule anti-cancer drugs. Under the terms of the agreement, Jing Medicine will receive global development and commercialization rights of anti-cancer molecules resulting from the collaboration with ShanghaiTech University. ShanghaiTech University will receive upfront and milestone payments and royalties.

Currently, Professor Jiang Biao’s lab has established a “Proteolysis Targeting Drugs Platform” with a library of novel compounds with secured patents.

"It’s important to translate our basic research accomplishments into clinical applications. Collaboration with Jing Medicine is a good beginning and will accelerate this process,” said Professor Jiang Biao, Executive Director of SIAIS at ShanghaiTech University.

"We are very excited to form this strategic collaboration with ShanghaiTech University to apply their protein degradation technology platform for drug discovery,” said Dr. Michael Xie, CEO of Jing Medicine. “This new technology has great potential in delivering differentiated medicines for cancer patients.”  

About ShanghaiTech University (

Officially approved to open on September 30th 2013 by China’s Ministry of Education, ShanghaiTech University is a small-scale research university of academic excellence jointly established by Shanghai Municipal Government and Chinese Academy of Sciences (CAS). ShanghaiTech is committed to serving the national development strategy. The University seeks innovative solutions to address the challenges that China is facing in the field of energy, material, environment, human health, thus to improve productivity driven by innovation, and contribute to the restructuring and development of China.

About SIAIS (

Founded by ShanghaiTech University on October 12th, 2012, the Shanghai Institute for Advanced Immunochemical Studies (SIAIS) aims to become a first-class, leading antibody research institute in the world. It focuses on elucidating the most fundamental problems in life science research, particularly in immunochemistry. Its international governing board is comprised of world recognized scientists, including pioneering antibody researchers and Nobel Prize winners.

SIAIS is building a state-of-the-art research organization dedicated to the understanding of the basic structure and design of biological molecules. It has eight key laboratories in the fields of antibody design, ADC chemistry, phenotypic screening, structure biochemistry, cell biology, stem cell biology, antibody engineering and antibody structure, covering all the capabilities that one needs to go from discovery of an important antibody through all the steps necessary to turn it into a drug.

About Jing Medicine (

Jing Medicine Technology (Shanghai) Ltd. is an innovation-driven biotech startup company focusing on turning cutting-edge science and technology into therapeutics. It was founded in early 2017 with $20 million USD in Series A financing.  Located on the campus of ShanghaiTech University, the mission of the company is to incubate, translate and commercialize life science research accomplishments at ShanghaiTech. Jing Medicine is committed to the development of therapeutic monoclonal antibody and small molecule drugs for the unmet medical needs in oncology, immunology, and neurology areas. Several research projects currently in the preclinical stage have their own intellectual properties. A number of programs have formed domestic and international collaboration.

The R&D management team is composed of senior executives and scientists from the United States and China, with extensive experience in world class biotech and pharmaceutical companies. The company is a foreign joint venture with investors which have strong background and excellent investment track record in the biotech and pharmaceutical industries. Our current investors include Shanghai Alliance Investment Ltd. (SAIL), WuXi AppTec (Shanghai) Co., Ltd., ZL China Holding Two (ZAI Lab), and Shanghai Cenova Xinghe Venture Capital Center, L.P.

To read more Press Release articles, click here.